Format

Send to

Choose Destination
Anticancer Res. 2018 Apr;38(4):2181-2185.

The Association of Matrix Metalloproteinase-8 Promoter Genotypes in Breast Cancer.

Author information

1
Terry Fox Cancer Research Laboratory, Translational Medical Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
2
Ph.D. Program for Biotechnology Industry, China Medical University, Taichung, Taiwan, R.O.C.
3
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
4
Department of Breast Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.
5
Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan, R.O.C.
6
Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
7
Terry Fox Cancer Research Laboratory, Translational Medical Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C. datian@mail.cmuh.org.tw artbau2@gmail.com.
8
Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.

Abstract

BACKGROUND/AIM:

The family of matrix metalloproteinases (MMPs) controls homeostasis of the extracellular matrix and their genetic polymorphisms may be associated with personal cancer susceptibility. The serum levels of MMP8 was reported to be higher in patients with breast cancer than in healthy individuals. In this study, we aimed to investigate the contribution of a polymorphism in the promoter region of MMP8 (-799C/T) and two nonsynonymous polymorphisms (Val436Ala and Lys460Thr) to breast cancer.

MATERIALS AND METHODS:

MMP8 -799C/T, Val436Ala and Lys460Thr polymorphic genotypes were determined for 1,232 patients with breast cancer and 1,232 healthy controls by polymerase chain reaction-restriction fragment length polymorphism methodology.

RESULTS:

The odds ratios (ORs) after adjusting for age, gender, smoking and alcohol drinking status for those carrying CT and TT genotypes at the MMP8 promoter C-799T were 1.03 (95% CI=0.88-1.23, p=0.7475) and 1.08 (95% CI=0.91-1.53, p=0.3561), respectively, compared to those carrying the wild-type CC genotype. The OR for the combined T-bearing genotypes were of a similar non-significant level (OR=1.05, 95% CI=0.90-1.26, p=0.5176). Supporting this finding, the adjusted OR for those carrying the T allele at MMP8 C-799T was 1.05 (95% CI=0.86-1.21, p=0.3797), compared to those carrying the wild-type C allele. There was also no significant association of MMP8 Lys460Thr with breast cancer. There was no polymorphic genotype at MMP8 Val436Ala found among any of the investigated individuals.

CONCLUSION:

MMP8 -799C/T, Val436Ala and Lys460Thr polymorphisms may only play an indirect role in determining personal cancer susceptibility to breast cancer in Taiwan.

KEYWORDS:

Breast cancer; MMP8; Taiwan; genotype; polymorphism

PMID:
29599337
DOI:
10.21873/anticanres.12459
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center